Singulex Inc., and Grifols partnership to develop Singulex' SMC technology for the screening of donor blood and plasma.

Singulex, Inc., the leader in next generation immunodiagnostic technology powered by single molecule counting, announced a partnership with Grifols, one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to scientific development. Grifols has subscribed a share capital increase and holds a 20% stake in Singulex. The partnership provides Singulex $50 million in exchange for Grifols' access to an exclusive worldwide license for the use and sale of Singulex' SMC technology for the screening of donor blood and plasma. Grifols' investment marks a major advancement in further ensuring the safety of blood and plasma products.